| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: O'Neill Gilmore Neil, Director
Sold 21,164 shares ($51.1K) |
| 13 Nov 2026 |
Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER
Sold 7,814 shares ($18.9K) |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia |
| 06 Nov 2026 |
Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER
Received 16,533 shares as a grant or award |
| 06 Nov 2026 |
Form 4: O'Neill Gilmore Neil, Director
Received 43,567 shares as a grant or award |
| 27 Oct 2026 | SCHEDULE 13G |
| 08 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering |
| 09 Sep 2026 |
Form 4: Ory Daniel Scott, EVP, Chief Medical Officer
Granted 950,000 Stock Option (right to buy) |
| 09 Sep 2026 |
Form 3: Ory Daniel Scott, EVP, Chief Medical Officer
No securities owned |
| 09 Sep 2026 | S-8 |
| 08 Sep 2026 | EFFECT |
| 04 Sep 2026 |
Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER
Sold 709 shares ($2.15K) |
| 04 Sep 2026 |
Form 4: Parison Amy, SVP, Chief Financial Officer
Sold 453 shares ($1.38K) |
| 04 Sep 2026 |
Form 4: O'Neill Gilmore Neil, Director
Sold 5,124 shares ($15.6K) |
| 31 Aug 2026 | S-3 |
| 31 Aug 2026 | 144 |
| 31 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G |
| 07 Aug 2026 |
Form 4: Ellinor Patrick Thomas Ii, Director
Granted 103,400 Stock Option (right to buy) |
Loading...